AOD-9604 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects. AOD-9604 is not fda-approved. development discontinued 2007. available as research chemical.
What Does the Research Say About AOD-9604?
12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
AOD-9604 (Fragment 177-191 of Human Growth Hormone (modified)) is a Lipolytic peptide, GH fragment analog. Research interest has focused on its potential effects on fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation.
What Is the Evidence for AOD-9604's Mechanism?
Activates beta-3 adrenergic receptors in adipose tissue, triggering cAMP-mediated lipolysis and release of stored fat for energy. Suppresses lipogenesis (new fat formation) while promoting fat breakdown. Unlike full growth hormone, it does not raise IGF-1 or impact glucose metabolism, blood sugar, or insulin sensitivity.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for AOD-9604?
12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, AOD-9604 has shown preliminary results.
What Does the Safety Research Show?
Well-tolerated across 900+ participants in clinical trials. Minimal adverse effects — potential mild headache, dizziness, or injection site reactions. One of the safest peptides in terms of documented human tolerability.
AOD-9604 is not fda-approved. development discontinued 2007. available as research chemical.
What Makes AOD-9604 Unique in Research?
The only GH fragment that selectively targets fat loss without any of growth hormone's effects on blood sugar, insulin, or IGF-1 — making it metabolically clean. The catch is that human efficacy was modest compared to impressive animal data.
This differentiator is important because it means AOD-9604 fills a role that other compounds in its class may not fully replicate.
Bottom Line on AOD-9604 Research
The evidence base for AOD-9604 is growing. Key research areas include fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation.
Stay current with PubMed searches for AOD-9604 for the latest publications.
Complete Guide
AOD-9604: The Fat Loss Peptide Fragment
Related Reading
- AOD-9604 Dosage Guide
- AOD-9604 Benefits
- AOD-9604 Side Effects
- AOD-9604 Stacking Guide
- AOD-9604 Cycle Guide
- CJC-1295 Complete Guide
Calculate Your AOD-9604 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for AOD-9604.
Open Calculator →Research-Grade Sourcing
If you're going to research AOD-9604, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 (Fragment 177-191 of Human Growth Hormone (modified)) is a Lipolytic peptide, GH fragment analog. Synthetic analog of human GH fragment 177-191, engineered to selectively activate lipolysis without systemic GH effects. It is researched for fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation.
What is the recommended AOD-9604 dosage?
Common dosages: 250-1000 mcg daily administered once daily, ideally morning fasted via subcutaneous injection. Cycle length: 12-24 weeks. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of AOD-9604?
Well-tolerated across 900+ participants in clinical trials. Minimal adverse effects — potential mild headache, dizziness, or injection site reactions. One of the safest peptides in terms of documented human tolerability.
Is AOD-9604 safe?
AOD-9604 has shown a favorable safety profile in research. Not FDA-approved. Development discontinued 2007. Available as research chemical. All research should follow appropriate safety protocols.